Global DNA Repair Drugs Market By Drug Type (Olaparib, Rucaparib, Niraparib, Talazoparib, and Other Drug Types), By Application (Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Breast Cancer, and Other Application Types) Growth, Future Prospects & Competitive Analysis, 2016 – 2030

Key Highlights of the Report

How are the major segments performing in the DNA Repair Drugs market?

• In 2022, the olaparib segment accounted for the largest market share as an increase in ovarian, breast, pancreatic, peritoneal, fallopian tube, and prostate cancer cases was increasing in demand.
• In 2022, the ovarian cancer segment was anticipated to hold a prominent share in the global DNA repair drugs market as it is the most common cancer among women and the most common cancer overall, ovarian cancer is the most common cancer among women
• In 2022, the hospital pharmacies segment accounted for the largest share of the market as there was an increase in the prevalence of cancer.

Which region dominated the DNA Repair Drugs market?

In 2022, the North American region was anticipated to hold a prominent share of the global DNA repair drugs market. As a result of increasing investments in DNA repair research, a greater focus on research and development, and an increasing prevalence of cancer disorders within the region, the market growth in the region has been fueled by these factors. In 2020, for example, 1,806,590 cases were diagnosed in the U.S., and the number of cancer survivors is expected to reach 2.2 million by 2030.

How is US Market Performing in the DNA Repair Drugs market?

In 2022, the North American region was anticipated to hold a prominent share of the global DNA repair drugs market. As there are a greater number of patients with breast cancer in the U.S. as a result, the demand for DNA repair drugs is high. Furthermore, the increased investment in R&D has fueled the region’s market demand.

How is the economy impacting the global DNA repair drugs growth?

As a result of the COVID-19 pandemic, DNA repair drugs have been affected significantly. DNA repair drugs are mostly used in cancer treatments. Consequently, the delay in cancer treatment worldwide led to a significant decline in demand for these drugs after the outbreak of the pandemic began. An article published in May 2021 titled “Impact of COVID-19 on Cancer Care in India: A Cohort Study” claims that the COVID-19 epidemic has significantly affected oncology services in India and the progression of cancer stages and outcomes. It is likely that discontinuing cancer screening and delaying hospital visits will have long-term consequences.

What is the competitive environment of the DNA repair drugs market?

In this sector, the competitive environment provides information on the total economic profit made by suppliers and businesses, the sales and revenue generated in this sector, the global share of DNA repair drugs, the business organization summary, the introduction of new products, and market opportunities for DNA repair drugs. For instance, in June 2021, the invention of prexasertib, an inhibitor of DNA damage response, was licensed to Acrivon Therapeutics by Eli Lilly for worldwide commercialization. As part of its Phase II development program, Acrivon will advance a dual inhibitor of CHK1 and CHK2 of the second generation called ACR-368. Furthermore, in February 2021, With the launch of ART0380, Artios Pharma Limited is undertaking a clinical trial to test the efficacy of its small-molecule ATR inhibitor against advanced or metastatic solid tumors. In combination with established and novel agents which cause DNA damage and suppress cancer’s ability to repair DNA damage, ART0380 is being developed as an oral anti-cancer drug for treating malignancies harboring defects in DNA repair.

Executive Summary

What are the key trends in the DNA repair drugs market?

Several key players are adopting research and development investments and strategies to develop new products. This factor is expected to boost the growth of the DNA repair drugs market. For instance, Artios Pharma announced in April 2018 that its next step was to develop a nuclease inhibitor drug program aimed at commercializing novel treatments for cancers of the breast, ovary, and other organs. As governments in developing countries modernize their healthcare infrastructure, access to healthcare is likely to increase. Consequently, government initiatives to increase cancer awareness and its growing prevalence in developing countries create lucrative market opportunities.

How are Manufacturers Teaming Up with Stakeholders in the DNA repair drugs market?

There are several key players in the global DNA repair drugs market, explaining the market’s high concentration level. Many manufacturers hold major market shares in their respective regions. Due to the rising prevalence of cancer, the demand for technologically advanced products has increased in both emerging and developed markets. There will be a strong drive to the global market from growth strategies adopted by leading players. For instance, in May 2019, it was announced that Clovis Oncology, Inc. had initiated a phase II study with Bristol-Myers Squibb Company and Foundation Medicine Inc. to evaluate the combination of rucaparib and nivolumab for the treatment of high-grade serous carcinoma (HGSC) and endometroid ovarian cancer.

Which are the key investments by the DNA repair drugs market players?

DNA repair drug market players are expanding production capacities for DNA repair drugs in order to gain a competitive advantage. Furthermore, players are focusing on strategic mergers and acquisitions, collaborations and creating awareness among healthcare industries through different associations formed to promote smart, innovative practices in order to serve more end users in the domestic market. For instance, in July 2017, A clinical collaboration between Bristol-Myers Squibb and Clovis Oncology was established. To evaluate their combined effects on multiple tumor types, Rubraca (Rucaparib) and Opdivo (Nivolumab) will be evaluated in Phase 2 and Phase 3 clinical trials.

Some major players in the DNA repair drugs market are Onxeo, FoRx Therapeutics, Artios Pharma Limited, Merck KGaA, Debiopharm Group, Breakpoint Therapeutics, Luciole Pharmaceuticals, Repare Therapeutics, AstraZeneca Plc, AbbVie, Johnson & Johnson, Pfizer Inc., ClovisOncology Inc., and GlaxoSmithKline plc.

What are the Major Driving Factors for the DNA repair drugs market?

Cancer is one of the leading causes of death globally. People are suffering from various cancer diseases; thus, the global DNA repair drugs market is likely to grow due to the increase in cancer prevalence among the population. The development of new products and adaptation of strategies for developing them are also hallmarks of several key players’ research and development efforts. As a result of governments in developing countries investing in modernizing healthcare infrastructure, healthcare access is likely to increase. Thus, government initiatives to raise awareness about cancer and its growing prevalence create lucrative market opportunities.

What are the Major Risks for the DNA repair drugs market?

The delays in product approvals, which can have a negative impact on revenue generation and increase clinical trial costs, are a major hindrance to the market’s expansion. In addition, the high cost of DNA repair drugs hinders the market growth.

Which is the key drug type in the DNA repair drugs market?

The olaparib segment is expected to hold a prominent share of the global DNA repair drugs market during the forecast period. Lynparza is the brand name under which Olaparib is sold. In adults with advanced BRCA-mutated ovarian cancer, it is a PARP inhibitor that inhibits the enzyme poly ADP ribose polymerase, which is involved in DNA repair. Ovarian, breast, pancreatic, peritoneal, fallopian tube, and prostate cancers are a few major factors driving the segment’s growth. For instance, Ovarian cancer, for instance, is the eighth most common cancer in women according to the World Cancer Research Fund International. There were over 313,000 new cases in 2020.

How is the DNA repair drugs market performing in regions?

North America is anticipated to witness the fastest growth in the global DNA repair drugs market during the forecast period due to the presence of key players and the introduction of new products following the early adoption of technologically advanced products. Furthermore, due to increasing investments in DNA repair research, a greater focus on research and development, and an increasing prevalence of cancer disorders within the region, the market growth in the region has been fuelled by these factors.

What is the regulatory landscape for the DNA Repair Drugs market?

Understanding DNA repair pathways from a biological and regulatory perspective may facilitate the development of inhibitors of nuclear and mitochondrial DNA repair pathways for increasing the anticancer effect of DNA damage-based therapies. As regulations and government initiatives build the growth of the DNA Damage Response Drugs market, business owners can anticipate what to expect in the future.

What is the Market Size of DNA Repair Drugs regarding value?

The global DNA repair drugs market is anticipated to grow at a substantial CAGR of 22.10% in the upcoming years. The global DNA repair drugs industry was estimated to be worth USD 7,894.6 million in 2022 and was expected to be worth USD 31,940.36 million by 2028.

What are the major players planning for the future of the DNA repair drugs market?

An increasing regional presence and investment in downstream applications are expected to give the company an advantage over its competitors. For instance, in October 2019, Janssen Pharmaceutical Companies’ niraparib was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) to treat metastatic castration-resistant prostate cancers caused by the BRCA1/2 gene mutation. Furthermore, in April 2018, A new venture by Artios Pharma aimed to commercialize new cancer treatments targeting nuclease inhibitors aimed at the female breast and ovarian cancers.

Segmentation of Global DNA Repair Drugs Market-

Global DNA Repair Drugs Market – By Drug Types

• Olaparib
• Rucaparib
• Niraparib
• Talazoparib
• Other Drug Types

Global DNA Repair Drugs Market – By Application

• Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer
• Breast Cancer
• Other Application Types

Global DNA Repair Drugs Market – By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Other Distribution Channel

Global DNA Repair Drugs Market – By Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • South-east Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa